LRMR — Larimar Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1374690 ·
Last close
$2.99
Market Cap
$310.61M
52W High
$6.42
52W Low
$1.91
ADV30
1,550,006
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -32,464,000 -31,135,000 140,504,000 76,986,000 39,038,000
Jun 2026 0 — -34,351,000 -32,782,000 165,302,000 92,687,000 37,920,000
Mar 2026 0 — -31,117,000 -29,613,000 208,511,000 177,913,000 50,478,000
Dec 2025 0 — -64,018,000 -62,498,000 145,842,000 85,412,000 67,757,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-155,924,000
Investing CF
$55,108,000
Financing CF
$172,766,000
CapEx
$-91,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.95
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-497,226,000
Inventory
—
Receivables
$267,000
ST Investments
$63,580,000
EBIT TTM
$-178,985,000
Pretax Income TTM
$-172,605,000
Interest Exp TTM
—
Analysts
10

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -172,497,000 -165,673,000 145,842,000 67,757,000 78,085,000 -113,201,000
Dec 2024 0 -90,890,000 -80,604,000 200,225,000 28,413,000 171,812,000 -70,760,000
Dec 2023 0 -41,758,000 -36,949,000 95,935,000 14,215,000 81,720,000 -33,459,000
Dec 2022 0 -36,526,000 -35,355,000 126,405,000 15,502,000 110,903,000 -27,569,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-172,605,000
OpCashFlow TTM
—
Assets (Latest)
$165,302,000
Forward EPS
$-1.06

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $3.23 · call oi: 1,226 · put oi: 83
Expected Move to 2027-01-15: ±$1.48 (45.89%) — implied range $1.75 – $4.71 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
INO INOVIO PHARMACEUTICALS, INC. $305.31M $1.63 —
AVIR Atea Pharmaceuticals, Inc. $318.00M $3.96 —
RLMD RELMADA THERAPEUTICS, INC. $321.15M $3.01 —
ALT Altimmune, Inc. $297.72M $1.53 —
GALT GALECTIN THERAPEUTICS INC $293.47M $2.91 —

News headlines (Yahoo Finance, 1h cache)

Larimar: Q3 Earnings Snapshot
2026-11-16 12:23 · Yahoo
Larimar Therapeutics Reports Third Quarter 2026 Financial and Business Update
2026-11-16 12:15 · Yahoo
Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
2026-11-09 21:05 · Yahoo
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
2026-11-05 21:05 · Yahoo
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-04 21:05 · Yahoo
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-10-05 12:35 · Yahoo
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
2026-09-29 20:05 · Yahoo
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
2026-07-15 15:43 · Yahoo
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
2026-07-08 22:44 · Yahoo
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
2026-07-03 13:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.